– New labeling approval for Abbott’s XIENCE™ stent builds on a legacy of safety and allows for one-month (as short as 28 days) dual anti-platelet therapy (DAPT) for patients at high bleeding risk (HBR) – The new XIENCE Skypoint™ stent […]
Tag: Xience
Newest Generation of Leading Heart Stent is Now Approved in the U.S. for People with Coronary Artery Disease
ABBOTT PARK, Ill., May 23, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced it received approval from the U.S. Food and Drug Administration (FDA) for XIENCE SierraTM, the newest generation of the company’s gold-standard XIENCE everolimus-eluting coronary stent system. XIENCE stents are among the […]
Abbott’s XIENCE Sierra™ Heart Stent Receives National Reimbursement in Japan to Treat People with Coronary Artery Disease
ABBOTT PARK, Ill., May 2, 2018 /PRNewswire/ — Abbott (NYSE: ABT) today announced that Japan’s Ministry of Health Labour and Welfare (MHLW) granted national reimbursement for XIENCE Sierra™, the newest generation of the company’s gold-standard XIENCE everolimus-eluting coronary stent. XIENCE Sierra improves upon previous versions […]
The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial; MiStent Achieved Primary Endpoint vs Xience®
DURHAM, N.C., Dec. 6, 2017 /PRNewswire/ — Micell Technologies, Inc. announced that The Lancet has published data from the DESSOLVE III clinical trial. The study met its primary endpoint, showing non-inferior safety and effectiveness outcomes in a complex patient population for the MiStent® Sirolimus Eluting […]
Abbott Shows off Landmark XIENCE Stent Data
DENVER, Oct. 30, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced that patients who underwent minimally-invasive implantation with a XIENCE coronary stent for left-main coronary artery disease had the same long-lasting health outcomes at three years but felt better more quickly than […]
ESC Congress 2017: BIOTRONIK’s Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
Landmark Data Published by The Lancet Demonstrates Statistically Significant Lower Event Rates with Orsiro BARCELONA, Spain, August 28, 2017 – BIOTRONIK today announced data from the BIOFLOW-V randomized trial comparing Orsiro1 and Xience2 drug-eluting stents (DES) with 12-month target lesion failure (TLF) […]
ABBOTT INITIATES CLINICAL TRIAL OF THREE-MONTH DUAL ANTIPLATELET THERAPY FOLLOWING IMPLANTATION WITH XIENCE CORONARY STENT
PRESS RELEASE ABBOTT PARK, Ill., July 25, 2017 — Abbott today announced that the first patient has been enrolled in a clinical study evaluating the short-term use of common blood thinning medicines, called dual antiplatelet therapy (DAPT), after receiving a […]
